The Effects of Pharmaceutical Innovation on Cancer Mortality

Margaret Kyle and Pierre Dubois

No 11487, CEPR Discussion Papers from C.E.P.R. Discussion Papers

Abstract: Cancer is a leading cause of death in developed countries, and cancer treatments are the top category of pharmaceutical spending in the United States and Europe. This paper assesses whether novel cancer therapies are associated with a reduction in mortality. Using panel data from 11 developed countries, we study the relationship between mortality attributed to a specific cancer site and the availability of pharmaceutical treatments. The cross-country and cross-site variation over time allows us to isolate the decline in mortality attributable to new drugs from that due to changes in lifestyle and environmental factors. We correct for the endogeneity of mortality and the availability of new treatments using instrumental variables. On average, our results show a decline in mortality of 8-9% is associated with the availability of one new treatment for a cancer site. The gains vary across countries and cancer sites. Based on spending from 2000-2011, costs per statistical life saved ranged from $11-12K for bladder and liver cancers to over $150K for cervical, melanoma and stomach cancers. Across countries, Switzerland had the largest spending per statistical life at approximately $66K, while the UK had the lowest with $19K.

Keywords: Pharmaceuticals; Cancer; Innovation; Health (search for similar items in EconPapers)
Date: 2016-09
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://cepr.org/publications/DP11487 (application/pdf)
CEPR Discussion Papers are free to download for our researchers, subscribers and members. If you fall into one of these categories but have trouble downloading our papers, please contact us at subscribers@cepr.org

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cpr:ceprdp:11487

Ordering information: This working paper can be ordered from
https://cepr.org/publications/DP11487

Access Statistics for this paper

More papers in CEPR Discussion Papers from C.E.P.R. Discussion Papers Centre for Economic Policy Research, 33 Great Sutton Street, London EC1V 0DX.
Bibliographic data for series maintained by ().